Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 8/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579467 | 1.00 | L3MBTL1 (0.44) | L3MBTL1METHRH3HCRTR1HCRTR2 | |
| SCHEMBL3587048 | 0.89 | ALOX5 (0.39) | L3MBTL1HRH3HCRTR1HCRTR2ALOX5 | |
| SCHEMBL12993585 | 0.89 | ALOX5 (0.39) | L3MBTL1HRH3HCRTR1HCRTR2ALOX5 | |
| SCHEMBL3587046 | 0.89 | ALOX5 (0.39) | L3MBTL1HRH3HCRTR1HCRTR2ALOX5 | |
| SCHEMBL3578481 | 0.85 | MET (0.45) | METHRH3 | |
| SCHEMBL3578478 | 0.85 | MET (0.45) | METHRH3 | |
| SCHEMBL3275616 | 0.82 | MET (0.48) | METHRH3HCRTR1HCRTR2 | |
| SCHEMBL3275620 | 0.82 | MET (0.48) | METHRH3HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL3275488 | 0.82 | MET (0.47) | METHRH3HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL3275486 | 0.82 | MET (0.47) | METHRH3HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | claimed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | claimed |
| JP-2008516952-A | — | — | 2008-05-22 | — | — | JP | claimed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | claimed |
| EP-1805169-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006044228-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | claimed |
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| EP-1805169-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044228-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | L3MBTL1 1782/4885MET 836/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.